Blog
RSS FeedPosted by Michael Wonder on 04 Apr 2017
Evaluation of evidence of statistical support and corroboration of sub-group claims in randomised clinical trials
3 April 2017 - Many published randomised clinical trials make claims for subgroup differences. ...
Posted by Michael Wonder on 28 Mar 2017
Emerging technology which aims to improve muscle movement is NICE’s 100th medtech innovation briefing
28 March 2017 - NICE’s advice series on new or novel healthcare technology reaches a milestone. ...
Posted by Michael Wonder on 23 Mar 2017
Call for experts in anonymisation of clinical data
23 March 2017 - EMA to set up technical group in the context of the publication of clinical data ...
Posted by Michael Wonder on 15 Mar 2017
Can a statistical method speed drug approvals?
13 March 2017 - Not likely, says F. Perry Wilson, MD. ...
Posted by Michael Wonder on 15 Mar 2017
Health Canada aims to release secret drug records
13 March 2017 - A proposed Health Canada policy would make public currently confidential information about drugs’ safety and efficacy. ...
Posted by Michael Wonder on 14 Mar 2017
Release of documents on two medicines temporarily halted
14 March 2017 - EMA’s appeals against interim measures are dismissed by Court of Justice ...
Posted by Michael Wonder on 13 Mar 2017
Review of the drug trials snapshots program of the US FDA: women in cardiovascular drug trials
13 March 2017 - Over the last 20 years, there have been concerns that too few women and minorities are enrolled ...
Posted by Michael Wonder on 10 Mar 2017
Statement from Health Canada on the publication of a white paper on public release of clinical information in drug submissions and medical device applications
9 March 2017 - Health Canada recognises that access to clinical information can help health researchers and practitioners, improve patient ...
Posted by Michael Wonder on 09 Mar 2017
UK children with cancer could miss out on drug trials after Brexit, doctors warn
9 March 2017 - Fears youngsters could be denied access to Europe-wide tests of new medicines when Britain leaves EU amid ...
Posted by Michael Wonder on 07 Mar 2017
Defining the non-inferiority margin and analysing non-inferiority: an overview
6 March 2017 - Non-inferiority trials are used to assess whether the effect of a new drug is not worse than ...
Posted by Michael Wonder on 01 Mar 2017
Public-private partnership speeds investigator access to cancer drugs
28 February 2017 - A new collaboration between pharmaceutical and biotech companies and the National Cancer Institute at the National ...
Posted by Michael Wonder on 27 Feb 2017
GSK ‘real world’ study offers new model for drug trials
27 February 2017 - Pharma groups look to evidence in normal medical settings to prove value for money. ...
Posted by Michael Wonder on 20 Feb 2017
The European Medicines Agency and publication of clinical study reports: a challenge for the US FDA
20 February 2017 - The US FDA has been the standard of drug regulation worldwide for decades. ...
Posted by Michael Wonder on 20 Feb 2017
Big pharma funding biases drug trials in favour of a sponsor's product: review
21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...
Posted by Michael Wonder on 14 Feb 2017
FDA drug trials snapshots and diversity when testing new drugs
13 February 2017 - Did you know that some drugs affect men and women differently? ...